NCCN Guidelines® Insights: Breast cancer, version 4.2021: Featured updates to the NCCN Guidelines Guidelines
| Authors: | Gradishar, W. J.; Moran, M. S.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K. H.; Blair, S. L.; Burstein, H. J.; Dang, C.; Elias, A. D.; Giordano, S. H.; Goetz, M. P.; Goldstein, L. J.; Hurvitz, S. A.; Isakoff, S. J.; Jankowitz, R. C.; Javid, S. H.; Krishnamurthy, J.; Leitch, M.; Lyons, J.; Matro, J.; Mayer, I. A.; Mortimer, J.; O'Regan, R. M.; Patel, S. A.; Pierce, L. J.; Rugo, H. S.; Sitapati, A.; Smith, K. L.; Smith, M. L.; Soliman, H.; Stringer-Reasor, E. M.; Telli, M. L.; Ward, J. H.; Wisinski, K. B.; Young, J. S.; Burns, J. L.; Kumar, R. |
| Title: | NCCN Guidelines® Insights: Breast cancer, version 4.2021: Featured updates to the NCCN Guidelines |
| Abstract: | The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer. © 2021 Harborside Press. All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 19 |
| Issue: | 5 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2021-05-01 |
| Start Page: | 484 |
| End Page: | 494 |
| Language: | English |
| DOI: | 10.6004/jnccn.2021.0023 |
| PUBMED: | 34794122 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2021 -- Source: Scopus |
